Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 19;6:66. doi: 10.1038/s41698-022-00301-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Overview of clinicopathological charteristics and clinical outcome of oncogene-mutant NSCLC treated with neoadjuvant immunotherapy. Clinicopathological charateristics including smoking status, therpeutic regimens, PD-L1 expression, treatment duration and preoperative radiologic response (according to Response Evaluation Criteria in Solid Tumors [RECIST]) were annotated for each patients. The horizontal dash line indicates the threshold for a major pathological response (90% regression). Pathological regression was presented in colored bar plot regarding different oncogene mutation. b Correlation between radiological shrinkage and pathological regression. Spearman correlation was used to measure the relevance. c Association between PD-L1 expression and MPR status. Centre line represents the median value of PD-L1 expression. Error bars represent the upper and lower quartiles of PD-L1 expression and whiskers defines the minimal and maximun value. PD Progression disease, SD Stable disease, PR Partial response, MPR Major pathological response, pCR Pathological complete response. d Disease-free survival (DFS) of all patients, EGFR-mutant patients and KRAS-mutant patients treated with neoadjuvant immunotherapy through Kaplan-Meier survival analysis.